Best for
Mobile

Posted
Angiogenex Inc (AGGX) is a leading other business based in the US. It opened the day at $0.25 after a previous close of $0.25. During the day the price has varied from a low of $0.25 to a high of $0.25. The latest price was $0.25 (25 minute delay). Angiogenex is listed on the PINK. All prices are listed in US Dollars.
Open | $0.25 |
---|---|
High | $0.25 |
Low | $0.25 |
Close | $0.25 |
Previous close | $0.25 |
Change | $0 |
Change % | 0% |
52-week range | $0.02 - $0.3 |
---|---|
50-day moving average | $0.25 |
200-day moving average | $0.1774 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Historical closes compared with the last close of $0.25
1 week (2021-02-22) | 0.25 |
---|---|
1 month (2021-02-04) | 0.25 |
3 months (2020-12-02) | 150.00% |
6 months (2020-09-02) | 53.85% |
1 year (2020-03-02) | 25.00% |
---|
Gross profit TTM | $0 |
---|---|
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | 0% |
TTM: trailing 12 months
We're not expecting Angiogenex to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Subscribe to trending stock alerts for a chance to win
AngioGenex, Inc. (AngioGenex) is a development-stage company. The Company is a biopharmaceutical company focused on the manufacturing of products for the treatment, diagnosis and prognosis of cancer. The Company focuses to develop orally active anti-cancer drugs that act by modulating the action of the inhibitor of differentiation (Id) proteins, measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer and generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases in which a surplus or deficit in the growth of blood vessels is an important part of the underlying pathology.
Learn more about Novo Integrated Sciences’ recent performance and where you can invest in Novo Integrated Sciences shares. We also run through some helpful rules of thumb for any investor
Learn more about Osprey Technology Acquisition’s recent performance and where you can invest in Osprey shares. We also run through some helpful rules of thumb for any investor.
Learn more about Churchill Capital IV’s recent performance and where you can invest in Churchill Capital IV. We also run through some helpful rules of thumb for any investor.
Learn more about Sunesis Pharmaceuticals’ recent performance and where you can invest in Sunesis shares. We also run through some helpful rules of thumb for any investor.
Learn more about Yunhong CTI’s recent performance and where you can invest in Yunhong shares. We also run through some helpful rules of thumb for any investor.
Learn more about Immunome’s recent performance and where you can invest in Immunome shares. We also run through some helpful rules of thumb for any investor.
Learn more about Natwest Group’s recent performance and where you can invest in Natwest shares. We also run through some helpful rules of thumb for any investor.
Learn more about Forest Road Acquisition’s recent performance and where you can invest in Forest Road Acquisition shares. We also run through some helpful rules of thumb for any investor.
Learn more about Kraken Robotics’ recent performance and where you can invest in Kraken Robotics shares. We also run through some helpful rules of thumb for any investor.
Learn more about Citius Pharmaceuticals’ recent performance and where you can invest in Citius Pharmaceuticals shares. We also run through some helpful rules of thumb for any investor.